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Epithelial-to-mesenchymal transition (EMT) is a critical
multistep process that converts epithelial cells to more
motile and invasive mesenchymal cells, contributing to
body patterning and morphogenesis during embryonic
development. In addition, both epithelial plasticity and
increasedmotility and invasiveness are essential for the
branching morphogenesis that occurs during develop-
ment of the mammary gland and during tumor forma-
tion, allowing cancer cells to escape from the primary
tumor. Cripto-1, a member of the epidermal growth
factor–Cripto-1/FRL-1/Cryptic (EGF/CFC) gene family,
together with the transforming growth factor (TGF)-
family ligand Nodal, regulates both cell movement and
EMT during embryonic development. During postnatal
development, Cripto-1 regulates the branching mor-
phogenesis of the mouse mammary gland and en-
hances both the invasive and migratory properties of
mammary epithelial cells in vitro. Furthermore, trans-
genic mouse models have shown that Cripto-1 pro-
motes the formation of mammary tumors that display
properties of EMT, including the down-regulation of the
cell surface adherens junctional protein E-cadherin and
the up-regulation of mesenchymal markers, such as vi-
mentin, N-cadherin, and Snail. Interestingly, Cripto-1 is
enriched in a subpopulation of embryonal, melanoma,
prostate, and pancreatic cancer cells that possess stem-
like characteristics. Therefore, Cripto-1 may play a
role during developmental EMT, and it may also be
involved in the reprogramming of differentiated
tumor cells into cancer stem cells through the in-
duction of an EMT program. (Am J Pathol 2012, 180:
2188–2200; http://dx.doi.org/10.1016/j.ajpath.2012.02.031)
The epithelial-to-mesenchymal transition (EMT) is a mul-
tistep process during which epithelial cells sequentially
2188lose their epithelial characteristics and acquire motility
and invasive properties that are characteristic of a mes-
enchymal phenotype.1 Cell surface adherens junctional
proteins, such as E-cadherin, and tight junction proteins,
such as occludins and claudins, mediate epithelial con-
nections between adjacent epithelial cells and are essen-
tial for both the maintenance of the epithelial cell pheno-
type and the preservation of apical-basal polarity. During
EMT, E-cadherin and other adherens junction and tight
junction proteins are down-regulated and replaced by
N-cadherin, providing more transient adhesive and mo-
tile properties.1 In addition, reorganization of cytoskeletal
elements, such as increases in actin stress fiber forma-
tion and in vimentin and smooth muscle actin expression,
allows the cells to acquire a more spindle-shaped form
and gain a mesenchymal phenotype, exhibiting front-to-
back, leading-edge polarity.1 Finally, the cells become
devoid of any intercellular contacts, and invade and mi-
grate along specific routes, possibly guided by collagen
fibrils and other extracellular matrix proteins to vascular
or lymphatic capillaries, where they intravasate. Once
they reach their final destination, such as an end-organ
metastatic site, extravasating mesenchymal cells reac-
quire their epithelial phenotype through a process known
as mesenchymal-to-epithelial transition (MET).2
Functional loss of E-cadherin is considered a hallmark
of EMT and is frequently observed at sites of EMT in both
embryonic development and cancer, especially at the
leading edge of tumors, inhibiting contact with activated
host stromal cells.1 EMT is triggered by a variety of ex-
tracellular growth factors, such as transforming growth
factor (TGF)-, fibroblast growth factors (FGFs), Wnts,
extracellular matrix proteins, and transcription factors,
that cooperate to reprogram epithelial cells into a mes-
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E-cadherin expression and induce expression of a mes-
enchymal gene signature include the zinc finger proteins
Snail and Slug, the basic helix loop helix factors Twist1
and Twist2, and the zinc finger E-box–binding homeobox
1 and 2, respectively.3
EMT is critical for gastrulation and neural crest cell
formation during embryogenesis and also plays a role
in fibrosis and wound healing in adult tissues.1 Aber-
rant activation of the developmental EMT program con-
tributes to tumor invasion, metastatic dissemination,
and acquisition of therapeutic resistance to chemo-
therapy and radiation. Numerous inducers of EMT dur-
ing embryonic development and cancer have been
identified.4 Cripto-1, a member of the epidermal growth
factor–Cripto-1/FRL-1/Cryptic (EGF/CFC) gene family,
is an example of a critical EMT inducer during embry-
onic development that is often reactivated in cancer
cells, regulating the multistep program of tumorigene-
sis.5 In this review article, we will illuminate the role
played by Cripto-1 as an EMT regulator during embryo-
genesis, mammary gland development, and tumori-
genesis, specifically in breast cancer progression.
Binding Partners and Intracellular Signaling
Pathways Modulated by Cripto-1
Cripto-1 has multiple binding partners and can modu-
late, in either a positive or a negative manner, a variety
of intracellular signaling pathways (Nagaoka et al6 pro-
vide an in-depth understating of the Cripto-1 signaling
network). Two of the major signaling pathways acti-
vated by Cripto-1 are the Nodal/Alk4/Alk7/Smad-2 sig-
naling pathway and the 78-kDa glucose-regulated
protein (GRP78)/Glypican-1/c-src/mitogen-activated
protein kinase (MAPK)/Akt signaling pathway.6
During embryogenesis, Cripto-1 functions primarily as
a coreceptor for the TGF- family ligands Nodal and
growth and differentiation factors (GDFs) 1 and 3, leading
to the activation of type I (Alk4/Alk7) serine-threonine
kinase receptors and the Activin type II receptor com-
plex, which triggers both the phosphorylation and activa-
tion of the Smad-2/Smad-3 intracellular signaling path-
way.6 Cripto-1 also interacts with other TGF- family
members, such as TGF-1 and Activins A and B, inter-
fering with the binding of these ligands to their cognate
receptors and attenuating TGF-1 and Activin A and B
signaling in multiple cell lines.6
In addition to functioning as a coreceptor for TGF-
family ligands, Cripto-1 can also bind to the glycosyl-
phosphatidyl-inositol–anchored heparan sulfate pro-
teoglycan glypican-1 or to the endoplasmic reticulum
protein GRP78 on the cell membrane, and it can induce
the activation of a c-src/MAPK/Akt signaling pathway,
promoting cell proliferation, motility, and survival.6 In-
deed, the activation of a c-src/MAPK/Akt signaling path-
way by Cripto-1 in a glypican-1– or GRP78-dependent
manner strongly correlates with Cripto-1 oncogenic ac-
tivity both in vitro and in vivo. Furthermore, Cripto-1 cross
talks with several other signaling pathways, including thetyrosine kinase receptor erbB4, Wnt/-catenin, Notch,
caveolin-1, and apelin pathways, indicating that the
Cripto-1 signaling pathway might have multiple cellular
functions.6
Cripto-1 in EMT during Embryonic
Development
EMT performs a critical role during embryonic develop-
ment, especially in gastrulation, which is a fundamental
process for the generation of the three primitive germ
layers.7 During gastrulation, ectodermal cells at the prim-
itive streak, because of signaling molecules generated
by the Spermann-Mangold organizer, undergo EMT (Fig-
ure 1). These cells migrate through the posterior region of
the primitive streak into the underlying tissue, producing
the primary mesenchyme or undergoing MET and form-
ing the underlying endoderm7 (Figure 1). TGF- super-
family members, such as Nodal, GDF1, and GDF3 and
their coreceptors Cripto-1, Wnt/-catenin, and FGF, have
been implicated in coordinately regulating tissue mor-
phogenesis during gastrulation7 (Figure 1). During early
mouse embryonic development, Cripto-1 expression is
initially detected in the inner cell mass of the blastocyst
and in extra-embryonic trophoblast cells before the gas-
trulation stage.5,8 In the epiblast before primitive streak
formation, asymmetric expression of Cripto-1 occurs in a
gradient (ie, in a proximal-distal manner). During the ini-
tial stages of gastrulation, localization of Cripto-1 occurs
at the nascent primitive streak and then spreads to the
embryonic mesoderm. Cripto-1 expression is signifi-
cantly reduced during the early neural lateral plate stage
and disappears in the late neural plate stage.5,8 Cripto-
1–null mice are embryonically lethal because of a lack of
embryonic mesoderm and a definitive endoderm.5,8 Sim-
ilarly, knockout mouse mutants of other EGF/CFC family
Figure 1. EMT during gastrulation. Gastrulation is a fundamental process for
the generation of the three primary germ layers: ectoderm, mesoderm, and
endoderm. Ectodermal cells at the primitive streak undergo EMT in response
to signaling molecules generated by the Spemann-Mangold organizer. These
cells migrate through the primitive streak into the underlying tissue, becom-
ing primary mesoderm. Ingressing cells can also undergo MET and produce
the endoderm.members, such as zebra fish one eyed pinhead (oep)
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ventral neuroectoderm and left/right laterality defects re-
sulting from abnormal gastrulation and defects in cell
movement.5,8 During gastrulation and lateral plate forma-
tion, the Notch1 and canonical Wnt/-catenin signaling
pathways are intimately involved in regulating the down-
stream expression of Nodal and Cripto-1, respec-
tively.9,10
The heart is the first organ to develop during em-
bryogenesis, and cardiac progenitor cells are initially
specified during the EMT program at gastrulation.11
Several studies indicate that Cripto-1 and canonical
Wnt/-catenin signaling are essential for cardiomyo-
cyte differentiation. In this regard, Cripto-1–null/ em-
bryonic stem (ES) cells lose their ability to form beating
cardiomyocytes, whereas the cardiomyocyte differen-
tiation program can be rescued by reintroducing a
Cripto-1–expressing gene into Cripto-1–null/
cells.12,13 Furthermore, the G-protein–coupled recep-
tor putative receptor protein related to Angiotensin-
type I receptor and its ligand apelin have been identi-
fied as downstream targets of Cripto-1 signaling during
the cardiomyocyte differentiation of ES cells, promot-
ing mesoderm patterning and cardiac specification.14
Interestingly, mutation analysis in human genomic DNA
suggests that a variant of the teratocarcinoma-derived
growth factor-1 (TDGF-1) gene encoding the Cripto-1
protein is associated with the development of a ven-
tricular septal defect, which is the most common con-
genital heart defect.15
In contrast, Liguori et al16 revealed the existence of a
stable neural regionalization of the anterior character in
Cripto-1–null/ embryos. Cripto-1–null/ embryos can
still form functional neural stem cells that are able to
differentiate and maintain a neural phenotype both in vivo
and in vitro.17 Cripto-1–null/ ES cells spontaneously
differentiate into neurons in the absence of retinoic acid,
indicating that Nodal and Cripto-1 are negative regula-
tors of neuroectoderm differentiation during embryogen-
esis.13 Furthermore, disruption of Cripto-1 expression in
mouse ES cells can enhance neurogenesis and midbrain
dopaminergic differentiation in vitro.18,19 These findings
suggest that Cripto-1 is a potential target for Parkinson’s
disease therapy, and mouse ES cells treated with a
Cripto-1–blocking peptide induce enhanced functional
recovery in a rat model of Parkinson’s disease.20
Whether all of the Cripto-1 activities during embryo-
genesis are Nodal dependent remains controversial. For
instance, null mutants for Cripto-1 and Nodal, although
they share several similarities, display significant differ-
ences in their phenotypes.5,8 However, Cryptic, a
Cripto-1 ortholog, or GDF1 and/or GDF3, which are ex-
pressed during embryogenesis, might compensate for
Cripto-1 or Nodal loss during embryogenesis. In fact, the
Cripto-1/Cryptic double mutant shows striking similarities
to the Nodal-null mutant phenotype, indicating that EGF/
CFC proteins are required for almost all of Nodal activities
during embryonic development.21
On the other hand, several studies have suggested
that Cripto-1 can function during embryogenesis inde-
pendently of Nodal. Cripto-1F78A/F78A mouse embryos,containing the amino acid substitution F78A, which fails
to activate the Nodal/Alk4/Smad-2 signaling pathway,
can initiate gastrulation movements and pattern anterior/
posterior axis formation, unlike Cripto-1–null mice.22 An-
other study has also shown that Cripto-1 uses a distinct
signaling pathway from Nodal in the induction of visceral
endoderm (VE) and anterior VE (AVE) differentiation. In
fact, extra-embryonic endodermal stem cells can differ-
entiate into VE and AVE by treatment with Nodal or
Cripto-1 in chimeric embryos. However, although the dif-
ferentiation program induced by Nodal is inhibited by
SB431542, a selective and potent inhibitor of Alk4/Alk5/
Alk7, differentiation of VE and AVE, stimulated by
Cripto-1, is unaffected by SB431542 treatment. These
results suggest that Cripto-1 can contribute to the differ-
entiation of VE and AVE independently of Nodal.23 Taken
together, it would appear that Cripto-1 and Nodal are
dependent on each other for signaling during embryo-
genesis, although different studies have shed light on
Cripto-1/Nodal-independent and Nodal/Cripto-1–inde-
pendent signaling pathways.
Cross Talk between Cripto-1 and Other EMT
Regulators in Embryogenesis and Cancer
TGF- Signaling Pathway
The TGF- signaling pathway is a critical inducer of EMT
in the context of development and during late-stage can-
cer progression.24 During embryogenesis, TGF- is re-
quired for heart valve formation and palatogenesis, pro-
cesses that require cell plasticity and EMT.25,26 In vitro
studies have shown that TGF- is a classic inducer of
EMT in a variety of systems. In breast cancer, TGF- can
function as a tumor suppressor in the early onset of
cancer or as a tumor promoter in later stages, probably
through its ability to induce EMT by interacting with the
ras, p38 MAPK, and Wnt/-catenin signaling pathways.24
The TGF- signaling pathway directly regulates the tran-
scription of classic EMT transcription factors, such as
Snail, Twist, and Slug (Figure 2).24 Conversely, TGF- is
a target of the transcription factors Snail and Slug.27 For
example, Snail- and Slug-overexpressing MCF-7 cells
show an increase in TGF- expression, enhanced acti-
vation of TGF- signaling, and an increased migratory
response, which are significantly reduced after treatment
with specific TGF- inhibitors.27 Nodal positively regu-
lates expression of Snail, Slug, and Twist in Xenopus,
possibly through the activation of NF-B.28 Interestingly,
Twist and Slug negatively regulate expression of Cer-
berus, a Nodal inhibitor, thereby increasing Nodal activity
and generating a positive feedback loop28 (Figure 2).
Cripto-1, in addition to mediating Nodal, GDF1, and
GDF3 signaling, can modulate signaling of other TGF-
family ligands, including Activin and TGF-. Cripto-1
binds to TGF-1 and interferes with the binding of
TGF-1 to the TGF- type I receptor, interfering with
TGF- signaling and tumor suppressor activity in a vari-
ety of cell lines.29,30 Similarly, Cripto-1 forms a complex
with Activins A and B, preventing the activation of an
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more, the heat shock protein GRP78 interacts with
Cripto-1 and potentiates the Cripto-1 inhibitory effects on
TGF- and Activin signaling.33,34 Interestingly, TGF-
family ligands, including TGF-1 and bone morphogenic
protein-4 (BMP-4), can directly regulate Cripto-1 gene
expression in both NTERA-2/D1 human embryonal carci-
noma (EC) cells and LS174-T human colon cancer cells
because of the presence of functional Smad-binding el-
ements within the Cripto-1 promoter region (Table
1).35–41 Surprisingly, although TGF-1 strongly enhances
Cripto-1 mRNA and protein expression, BMP-4 down-
regulates Cripto-1 expression and interferes with Cripto-1
oncogenic activity in vitro. In fact, BMP-4 inhibits migra-
tion of LS174-T cells and induces differentiation of
NTERA-2/D1 cells.35 Therefore, Cripto-1 might play a role
in restraining the TGF- cytostatic program while promot-
ing TGF- protumorigenic effects in late stages of onco-
genic transformation. In fact, TGF- signaling might pro-
mote tumorigenesis, in part, through the direct induction
of Cripto-1 expression, which, in turn, attenuates TGF-
cytostatic effects while increasing proliferation, motility,
invasion, and EMT of tumor cells (Figure 2 and Table 1).
Figure 2. Cross talk of Cripto-1 with other EMT signaling pathways. Cripto-1
cooperates with several EMT signaling pathways in the induction of EMT in
both embryogenesis and cancer. Cross talk of Cripto-1 with other EMT
inducers is described in detail in the text. HIF, hypoxia-inducible factor.
Table 1. Regulation of Cripto-1 Expression
Type of regulator Regulators mRNA a
Positive
Growth factors TGF-1 mRN
Wnt/-catenin mRN
Transcription factors HIF-1 mRN
Msx2 mRN
Nanog mRN
Oct-4 mRN
Negative
Growth factors BMP-4 mRN
Transcription factors Netrin-1 mRN
GCNF mRNGCNF, germ cell nuclear factor; RT-qPCR, quantitative RT-PCR; WB, WesterHowever, the potential cooperation between Cripto-1 and
TGF- signaling in promoting cell motility, invasion, and
EMT in advanced tumors requires further investigation.
Canonical Wnt/-Catenin Signaling Pathway
Similar to Cripto-1, the canonical Wnt/-catenin signaling
pathway is implicated in EMT during development and
cancer.41 The Wnt/-catenin signaling pathway can reg-
ulate EMT during gastrulation and cardiac valve forma-
tion.41 Cross talk between Wnt/-catenin and Cripto-1
has been clearly demonstrated during embryonic devel-
opment (Figure 2). For instance, Cripto-1 expression is
lost in -catenin–knockout embryos.10 Interestingly, both
-catenin– and Cripto-1–knockout embryos show similar
phenotypes that are characterized by the absence of an
anteroposterior axis. Wnt3-knockout embryos also show
down-regulation of Cripto-1 expression, although the lev-
els of Cripto-1 down-regulation are not as dramatic as in
the -catenin–knockout embryos. The direct regulation of
Cripto-1 expression by -catenin is dependent on the
presence of T-cell factor/lymphoid enhancer factor–bind-
ing elements in the promoter and first intronic region of
the human Cripto-1 gene (Table 1).36 Studies in Xenopus
have also shown that one of the six Cripto-1 orthologs in
Xenopus, FRL-1, directly binds to Wnt11 and, together
with the glycosyl-phosphatidyl-inositol–linked proteogly-
can Glypican-4, activates the canonical Wnt/-catenin
signaling.42 FRL-1 and Wnt11 are both essential for dor-
sal axis formation in Xenopus embryos and, therefore,
Wnt11- and FRL-1–depleted embryos show similar phe-
notypes.42
The Wnt/-catenin pathway also plays a key role dur-
ing mammary gland development, regulating the forma-
tion of the mammary placodes during midgestation (E10)
and postnatally by promoting side branching in the virgin
mammary gland and alveolar differentiation during preg-
nancy.43 Multiple Wnt ligands and their receptors are
expressed in cells composing the terminal end buds
(TEBs), which are the sites of active epithelial growth and
migration in the virgin mammary gland.43 Moreover, Wnt1
overexpression in the mouse mammary gland, under the
control of the mouse mammary tumor virus (MMTV) pro-
moter, induces epithelial hyperbranching and precocious
alveolar differentiation.44 A functional link between Wnt/
rotein Methods Ref. no.
ein RT-qPCR, WB 35
RT-qPCR 36
ein RT-qPCR, WB 37
ein Semiquantitative RT-PCR, WB 38
Microarray 39
Microarray 39
ein RT-qPCR, WB 35
ein RT-qPCR, WB 40
Northern blot 41nd/or p
A/prot
A
A/prot
A/prot
A
A
A/prot
A/prot
An blot.
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supported by the observation that Cripto-1 overexpres-
sion in the mouse mammary gland is associated with an
increase in the activated, dephosphorylated form of
-catenin and an increase in the inactive, phosphorylated
form of glycogen synthase kinase-3.45 Conversely, an
increase in Cripto-1 expression has been detected by
immunohistochemistry in MMTV-Wnt1 mammary tumors,
indicating that Cripto-1 might be a mediator of the effects
of activated Wnt/-catenin signaling in the mammary
gland during tumorigenesis.46
In vitro studies have also implicated Wnt/-catenin sig-
naling in epithelial plasticity and EMT. Activation of the Wnt/
-catenin pathway in breast cancer cells induces the EMT
regulators Snail and Twist and up-regulates the mesenchy-
mal marker vimentin (Figure 2).47–49 Conversely, Twist-
overexpressingMCF-7 breast cancer cells activate theWnt/
-catenin signaling pathway and induce expression of
CD44 and aldehyde dehydrogenase 1, stem cell markers
associated with EMT.50
Brachyury
Brachyury, a T-box transcription factor, is required for
both normal gastrulation movements and posterior me-
soderm formation during embryogenesis (Figure 1).
Brachyury is a direct transcriptional target of the FGF and
canonical Wnt/-catenin signaling pathways (Figure
2).51,52 Moreover, Brachyury regulates the expression of
Wnt3a and Wnt8, suggesting that a positive autoregula-
tory loop between Brachyury and the canonical Wnt/-
catenin signaling pathway might occur during embryo-
genesis.53 Notably, Cripto-1 is also essential for the up-
regulation of Brachyury expression in response to Wnt/-
catenin signaling in P19 EC cells and by Nkx2.5 in
cardiomyocyte precursor cells (Figure 2).54,55 In fact,
both Brachyury and Nkx2.5 are essential inducers of
mesoendodermal cells that are committed to a cardiomy-
ocyte lineage. The embryonic, pluripotential stem cell
transcription factor Oct-4 positively regulates Cripto-1 ex-
pression in P19 cells, which, in turn, allows Brachyury to
respond to Wnt/-catenin signaling. This finding might be
significant, because Brachyury overexpression in tumor
cells leads to the acquisition of an EMT phenotype and an
increase in both cell migration and invasion.56 Further-
more, Brachyury is overexpressed in various human tu-
mor tissues and cancer cell lines, and has been associ-
ated with advanced human lung tumors.56 Because
Cripto-1 has been involved in the induction of EMT in
cancer, Brachyury might represent a downstream target
of Cripto-1 in a feed-forward regulatory loop for control-
ling the induction of EMT in cancer cells.
Cripto-1 Functions in Mammary Gland
Development and Tumorigenesis
The mammary gland is a unique organ because most of
its developmental program occurs postnatally. During
embryogenesis, mammary glands are specified early
during midgestation, with the formation of the mammarymilk lines on the ventral surface of the embryo at E8.5.57
Ectodermal cells along the mammary lines aggregate
and form mammary placodes or buds at E10.5. The pla-
codes invaginate into the underlying ventral dermal
stroma, and epithelial bud cells proliferate and form a
branching duct-like tree in the surrounding stromal mes-
enchyme, producing a rudimentary mammary gland.
Postnatally, during puberty at the age of 3 to 4 weeks, the
mammary gland begins to elongate with the formation of
highly proliferative TEBs that invade the mammary fat
pad and produce an extensive network of branching
ducts that fill the mammary fat pad.58 During pregnancy,
the mammary gland undergoes alveolar development
and side branching in preparation for lactation. On ces-
sation of lactation and during involution, the gland re-
gresses to its previous state.
During branching morphogenesis in the postpubes-
cent gland, cap cells at the leading edge of the TEBs
exhibit features of epithelial plasticity, acquiring a tran-
sient mesenchymal-like phenotype necessary for the
generation of an intricate mammary ductal tree.58 Epithe-
lial cell plasticity of the developing mammary gland is
influenced by pituitary hormones (eg, prolactin), ovarian
hormones (eg, estrogen and progesterone), and locally
derived growth factors [eg, amphiregulin, insulin-like
growth factor-1 and insulin-like growth factor-2, hepato-
cyte growth factor (HGF), Wnt4 and Wnt5a, FGFs, colony-
stimulating factor (CSF)-1, and TGF-1], which can be
expressed in the epithelial cells, stroma, adipocytes,
mast cells, or macrophages that surround the TEBs.58 An
analysis of the temporal expression of Cripto-1 in the
developing mammary gland indicates that Cripto-1 is
expressed during embryonic and postnatal mammary
gland development. Strizzi et al40 have found that
Cripto-1 can be detected in the mesenchyme surround-
ing the mammary placodes but not in the epithelial pla-
codes, similar to Msx2, Lef-1, and -catenin in the Wnt
pathway, suggesting that Cripto-1 might be important for
mammary mesenchymal development.
Postnatally, Cripto-1 can be detected at low levels in
ductal epithelial cells of the virgin mouse mammary
gland, and its expression significantly increases during
pregnancy and lactation, with its expression also being
detected in human milk.59–61 Cripto-1 has been localized
in myoepithelial, luminal epithelial, and cap cells of the
advancing TEBs of the branching ducts of the virgin
mouse mammary gland.60 Because cap cells of TEBs
exhibit signs of epithelial plasticity (eg, loss of apical-
basal polarity) or secretion of extracellular metallopro-
teases, activation of Cripto-1 in these cells might contrib-
ute to the induction of epithelial plasticity, EMT, and
ductal invasion into the mammary fat pad during mam-
mary gland development.
Several studies have clearly shown that Cripto-1 is
involved in regulating branching morphogenesis and
EMT of the mammary gland both in vitro and in vivo.
Kenney et al59 first demonstrated that recombinant
Cripto-1 that had been incorporated into Elvax slow-re-
lease implants and inserted into the mammary gland of
virgin mice promoted a de novo network of branching
ducts migrating toward the pellet. These dramatic
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observed in vitro. For example, treatment of cobblestone-
like NOG-8 mouse mammary epithelial cell colonies (Fig-
ure 3A) with recombinant Cripto-1 for several days can
induce scattering of peripheral epithelial cells, which
acquire more fibroblastic-like morphological charac-
teristics (Figure 3B). In contrast, untreated control
NOG8 cells continue to grow in tight colonies without
showing any morphological changes (Figure 3A). In
addition, overexpression of Cripto-1 in EpH4 mouse
mammary epithelial cells induces the extensive forma-
tion of branching, duct-like structures that contain a
lumen when grown in a three-dimensional collagen
type I matrix (Figure 3, C and D).
Remarkably, Cripto-1–expressing mammary epithelial
cells also show enhanced migration and invasion capac-
ity in vitro compared with control mammary epithelial
cells.62 However, this increase in cell motility in response
to Cripto-1 overexpression is not unique to mammary
epithelial cells, because it has also been demonstrated in
a variety of cancer cell lines. For instance, MCF-7 breast
cancer cells and Caski human cervical carcinoma cells
overexpressing Cripto-1, or LS174-T colon cancer or
NTERA-2/D1 EC cells that express endogenous Cripto-1,
show a significant increase in their migration and invasion
Figure 3. Effects of Cripto-1 on morphological characteristics and branching
morphogenesis of mouse mammary epithelial cells. NOG-8 mouse mammary
epithelial cells were grown on plastic as colonies in the absence (A) or
presence (B) of recombinant Cripto-1 protein (50 ng/mL) (R&D Systems,
Minneapolis, MN) for 8 days. Cripto-1 treatment induces scattering of pe-
ripheral epithelial cells, which acquire more fibroblastic-like morphological
characteristics (B). EpH4 wild-type (C) and EpH4 Cripto-1 cells (D) were
grown in collagen type I matrix for 2 weeks. Cripto-1 overexpression induces
the extensive formation of branching duct-like structures that contain a
lumen (D) compared with EpH4 control cells (C).behaviors compared with parental cell lines.8,35,63 Inter-estingly, Cripto-1 overexpression in Caski cells also in-
duces a more invasive mesenchymal phenotype, as
demonstrated by the dramatic increase in vimentin
mRNA and protein expression in Cripto-1–Caski cells
compared with wild-type control cells.63
Transgenic mouse studies46,64 have confirmed the di-
rect involvement of Cripto-1 in mammary gland branch-
ing morphogenesis and tumorigenesis. In fact, nullipa-
rous transgenic female mice expressing the human
Cripto-1 transgene in the mammary gland under the tran-
scriptional control of the MMTV promoter (MMTV–
Cripto-1 mice) exhibit dramatic morphological changes
in the nulliparous virgin mammary gland, specifically dis-
playing a significant increase in lateral secondary and
tertiary side branching (compare Figure 4, A and B, with
Figure 4, C and D, respectively). Mammary glands from
MMTV–Cripto-1 mice also exhibit regions of focal prolif-
eration (Figure 4B) that, on histological analysis, were
confirmed to be intraductal epithelial hyperplasias. Aged
multiparous MMTV–Cripto-1 mice exhibit pronounced
mammary multifocal hyperplasias and papillary adeno-
carcinomas, suggesting that Cripto-1 requires additional
genetic alterations to promote mammary tumor formation,
because tumor formation requires multiparity and the tu-
mor frequency is between 40% and 50% in MMTV–
Cripto-1 mice.46 Remarkably, mammary tumors from
MMTV–Cripto-1 transgenic mice exhibit areas of morpho-
logical changes associated with EMT.45 In fact, MMTV–
Cripto-1 mammary tumors show a reduction of intercel-
lular adhesion proteins, such as E-cadherin, and an
increase in the expression of mesenchymal markers, in-
cluding N-cadherin and vimentin.
Increased expression of several integrins, including
integrins 3, 5, 1, 3, and 4, is also detected in
MMTV–Cripto-1 mammary tumors, thereby promoting the
activation of focal adhesion kinase, which leads to cell
spreading. Furthermore, MMTV–Cripto-1 tumors exhibit
an increased activation of c-src and Akt intracellular sig-
naling pathways; phosphorylated and inactive glycogen
synthase kinase-3; nuclear, dephosphorylated, and ac-
tive -catenin; and enhanced levels of cyclin D1. The
zinc-finger transcription factor Snail is also expressed in
MMTV–Cripto-1 mammary tumors, suggesting that it
might be directly involved in the down-regulation of E-
cadherin observed in these lesions (Figure 2). Notably,
positive staining for Snail, vimentin, N-cadherin, and cy-
clin D1 is generally restricted to the undifferentiated ar-
eas of the tumor that contain large undifferentiated cells
with mesenchyme-like morphological characteristics.45
Markers of EMT could also be detected in uterine leio-
myosarcomas that develop in approximately 20% of nul-
liparous or multiparous MMTV–Cripto-1 mice.65
Transgenic mice that overexpress the human Cripto-1
transgene in the mammary gland under the transcrip-
tional control of the whey acidic protein promoter also
develop mammary tumors in multiparous mice that, un-
like the adenocarcinomas in MMTV–Cripto-1 mice, dis-
play a variety of histological subtypes that resemble the
histological characteristics of mammary tumors that arise
in transgenic mice overexpressing Wnt1 or activated
forms of -catenin.64,66,67 This finding suggests that
and D). Arrows, hyperplastic regions. Original magnification: 1 (A and C);
5 (B and D).
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cell population in whey acidic protein–Cripto-1 mice that
can produce multiple histological subtypes, as has been
observed in MMTV-Wnt1 and MMTV-activated -catenin
mice.68,69
HC-11 mouse mammary epithelial cells overexpress-
ing Cripto-1 (HC-11/Cripto-1) also undergo EMT, as
shown by a decrease in E-cadherin expression and an
increase in vimentin, N-cadherin, and Snail expression.45
In addition, signaling molecules that are known to be
activated during EMT, such as c-src, focal adhesion ki-
nase, and Akt, are highly phosphorylated in HC-11/
Cripto-1 cells compared with HC-11 control cells. Inter-
estingly, the c-src inhibitor PP2 inhibited activation and
phosphorylation of c-src, focal adhesion kinase, and Akt
in HC-11/Cripto-1 cells and strongly interfered with their
migratory behaviors, indicating that activation of c-src by
Cripto-1 is critical for mammary epithelial cell migration.45
Intriguingly, Netrin-1, a neural axon guidance protein and
a Nodal target gene in embryonic lateral plate meso-
derm, antagonized Cripto-1–induced EMT, migration,
and the ability of Cripto-1 to attenuate -casein expres-
sion in HC-11/Cripto-1 cells in response to lactogenic
hormones (Table 1).80 In fact, Cripto-1 fibroblastic-like
cells became more epithelial in their morphological char-
acteristics, suggesting that Netrin-1 might promote MET
in the context of Cripto-1 overexpression.80
di Bari et al38 have shown that Cripto-1 is a down-
stream target of the transcription factor Msx2 (Figure 2
and Table 1). Msx2, like Cripto-1, is expressed at sites of
EMT during embryogenesis and in the mammary embry-
onic mesenchyme, and promotes branching morphogen-
esis of the mammary gland.81 Overexpression of Msx2 in
NMuMG mouse mammary epithelial cells induces EMT
through the up-regulation of Cripto-1 expression. Inhibi-
tion of Cripto-1 expression, using a specific anti-Cripto-1
small-interfering RNA or blockade of the c-src signaling
pathway, converts the mesenchymal phenotype of
NMuMG Msx2-expressing cells into more epithelial mor-
phological characteristics.38 Interestingly, Msx2 is co-
expressed with Cripto-1 and activated c-src in tissue
sections obtained from a small cohort of infiltrating breast
carcinomas, indicating that the cross talk between Msx2
and Cripto-1 might be involved in mammary tumor pro-
gression and invasion.
Furthermore, Cripto-1 has been overexpressed in a
variety of human tumors and human cancer cell lines,
whereas low or undetectable levels of expression are
detected in normal adult tissues and in non-transformed
normal cell lines (Table 2).8,65,70-79 The function of
Cripto-1 in regulating EMT in cancer cells might explain
the association of its expression with more aggressive
behavior in several types of cancers, as shown in Table 2.
Increased Cripto-1 expression and decreased E-cad-
herin expression have been positively associated with
tumor progression and poor prognosis in patients with
gastric and breast cancers.70,72 A positive correlation
between high levels of Cripto-1 expression and prognos-
tic factors (eg, tumor size, depth of invasion, lymph node
metastasis, liver metastasis, and TNM stage) has beenFigure 4. Whole mount histological features of mammary glands from nul-
liparous virgin MMTV–Cripto-1 and wild-type FVB/N mice. Virgin MMTV–
Cripto-1 mammary glands (A and B) exhibit more secondary and tertiary
ductal side branching compared with wild-type control mammary glands (Cdetected in gastric cancer.70 Furthermore, high levels of
e RT-PC
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represent independent prognostic factors in gastric can-
cer, suggesting that combined analysis of Cripto-1 and
E-cadherin might have a significant value in predicting
patient prognosis and in evaluating the metastatic poten-
tial of gastric cancer.70 Cripto-1 overexpression is also
Table 2. Cripto-1 Expression in Human Cancer Cell Lines and H
Tissue
Cripto-1 mRNA and/or pr
Human cancer cell lines
Bladder NA
Breast MCF-7, ZR-75-1, T-47D, MDA-MB-231,
SkBr3, and MDA-MB-4688,71
Cervix NA
Colon GEO, DLD-1, CoLo201, Sw620,
LS174T, CBS, HT-29, HCT116, and
LoVo8
Endometrium NA
Eye OCM-1, OCM-8, 92–1, and OMM-18
Gallbladder NA
Lung NA
Nasopharynx NA
Oral cavity SCC-15, HSC-2, HSC-3, HSC-4, HO-1-
N1, KOSCC-11, KOSCC-25B, and
KOSCC-33A75
Ovary NIH_OVCAR3, NIH_OVCAR4, and
NIH_OVCAR876
Pancreas NA
Prostate DU145, LNCap, and PC38,78
Skin ROS184, CON242, COPA159, and
C8168,31
Stomach HSC398
Testis NTERA-2 and NCCIT8,31
Uterus NA
*As detected by using Northern blot, quantitative and semiquantitativ
NA, not available; PR, progesterone receptor.found in high-grade and poor-prognosis breast tumorscompared with low-grade and good-prognosis breast
cancers.72
Nodal has been a key regulator of melanoma tumori-
genicity, promoting the migration and invasion of mela-
noma cells.82 Nodal expression correlates with both mel-
anoma progression and advanced breast cancer.82,83 In
umors
xpression*
Clinical correlationsHuman tumors
der cancer8 NA
st cancer8,72,73 High histological grade, PR
positive, high Ki–67
index, Nottingham
Prognostic Index 5.4,
invasive ductal or lobular
carcinomas, decreased
survival
ical carcinoma8 High tumor size,
lymphovascular
involvement, endometrial
and parametrial
extension, lymph node
metastasis
n cancer8 Advanced tumor stage,
high Ki-67 index,
lymphovascular
involvement,
metachronous
metastasis, decreased
survival, poor prognosis
metrial carcinoma8,74 High histological grade,
advanced surgical stage,
myometrial invasion,
positive peritoneal
washing cytology
l melanoma8 Extrascleral extension, liver
metastasis
ladder carcinoma8 Papillary and well-
differentiated tumors
carcinoma8 NA
pharyngeal cancer8 Lymph node metastasis,
distant metastasis,
advanced clinical stage
squamous cell carcinoma75 Moderately/poorly
differentiated tumors
ian carcinoma8 Advanced tumor stage
reatic cancer8 Advanced tumor stage
NA
noma78 and basal cell
rcinoma8
NA
ric cancer8,70,79 Advanced tumor stage,
poor prognosis, lymph
node metastasis, distant
metastasis, histological
intestinal type,
moderately differentiated
tumors
nomas and nonseminomas
bryonal carcinomas,
atocarcinomas, and
oriocarcinomas)8
NA
yosarcoma of the uterus65 NA
R, Western blot, or immunohistochemical analysis.uman T
otein e
Blad
Brea
Cerv
Colo
Endo
Uvea
Gallb
Lung
Naso
Oral
Ovar
Panc
NA
Mela
ca
Gast
Semi
(em
ter
ch
Leiomfact, Nodal depletion in aggressive melanoma cells de-
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cell plasticity.82 Nodal can positively regulate the expres-
sion of the EMT regulators Twist, Snail, and Slug during
mesoderm formation in Xenopus (Figure 2).28 Twist and
Slug, in turn, negatively affect the expression of Cer-
berus, a Nodal antagonist (Figure 2).28 A recent report
showed that Cripto-1 might also function in human mel-
anomas. De Luca et al78 detected Cripto-1 expression in
43% of primary human cutaneous melanomas and in
57% of melanoma cell lines (Table 2). Notably, Cripto-1
strongly enhanced the motility of melanoma cell lines;
blockade of c-src and Nodal signaling with specific in-
hibitors or interference of Cripto-1 expression using
small-interfering RNAs produced a significant inhibition
of the growth and the invasive ability of melanoma cells.78
These results suggest that Cripto-1 and Nodal might co-
operate in the induction of a more aggressive phenotype
in human melanomas and possibly in other tumors, such
as breast cancer.
Cripto-1 in Embryonic Cells and CSCs
Stem cells can have two distinct functions: They divide
either symmetrically for an uncertain period of time, main-
taining their undifferentiated state (self-renewal), or
asymmetrically, to generate progenitor, transamplifying
cells that can differentiate into distinct cell types through-
out early development and in adult tissues.84 In the de-
veloping embryo, stem cells can produce all three pri-
mary germ layers: ectoderm, endoderm, and mesoderm.
In adult organisms, stem cells and progenitor cells can
be found in different tissue types and function as an
internal repair system, dividing to replenish specialized
cells and maintaining normal turnover of regenerative
organs, such as blood, skin, and intestinal tissues.84
During the past several years, a large effort has been
made to identify new stem cell markers in an attempt to
isolate stem cell populations, especially because of their
potential as targets for therapeutic intervention. By using
human ES cells, a subset of genes has been identified as
potential stem cell markers, including Nanog, Oct4, con-
nexin 43 (GJA1), and TDGF-1/Cripto-1.5 Interestingly,
analysis across species has found a set of common
highly conserved signaling pathways in both mouse and
human ES cells, including TDGF-1/Cripto-1, Oct-4, Lefty,
Nodal, Sox-2, undifferentiated embryonic cell transcrip-
tion factor-1, and telomerase reverse transcriptase.5 Re-
markably, Loh et al39 found that Cripto-1 is a direct down-
stream target gene of the ES pluripotential transcription
factors Oct-4 and Nanog (Figure 2 and Table 1). Recip-
rocally, Activin, Nodal, and Cripto-1 are essential in initi-
ating and maintaining the expression of Nanog and Oct-4
(Figure 2).85 Moreover, some of the ES cell markers, such
as Oct-4, Sox-2, Kfl4, and c-Myc, can reprogram human
fibroblasts to generate pluripotent cells, also known as
induced pluripotent stem cells (iPSCs).86 Conversely, hu-
man iPSCs express ES cell genes (Sox15, SALL4, Dax1,
Zfp296, FGF4, Sox10, and TDGF-1/Cripto-1), exhibit ES
growth properties, and can be selectively channeled into
differentiated cells from the three germ layers.5 Severalmechanisms have regulated the expression of embryonic
genes in iPSCs and ES cells, including DNA methyl-
ation.87 For example, 23 genes, including Sox15, SALL4,
Oct-4, and TDGF-1/Cripto-1, are hypomethylated in iP-
SCs/ES cells and are, therefore, highly expressed.87 Re-
ciprocally, in all somatic tissues, most cells exhibit hyper-
methylation of genes, such as Nanog, Oct-4, Stellar, and
TDGF-1/Cripto-1.88
In addition to embryonic development and adult re-
generative tissues, a subpopulation of cells that share
characteristics associated with normal stem cells has
been identified in human tumors. These cancer stem
cells (CSCs), also called tumor-initiating cells, are iden-
tified by their ability to self-renew and initiate new tumors
of a similar phenotype when injected in small numbers
into immunodeficient mice.89 Moreover, CSCs are pro-
posed to endure in tumors as a distinct population and
may lead to tumor relapse and/or metastasis because
they are chemoresistant and radioresistant.5,8,89 Similar-
ities between embryonic development and cell transfor-
mation during oncogenesis have led to the identification
of common signaling pathways, such as the Wnt/-
catenin, Hedgehog, and Notch pathways, suggesting
that the inappropriate reactivation of developmental pro-
grams in a subpopulation of stem-like cells might drive
cell transformation and tumor progression in adult tis-
sues.5 For example, EMT is an essential developmental
program that can be inappropriately activated in cancer
cells and can induce the formation of migratory mesen-
chymal cells that possess invasive properties and meta-
static potential.90
Furthermore, recent evidence suggests that adult cells
that undergo EMT acquire stem cell–like properties.91,92
Al-Hajj et al93 separated tumorigenic from nontumori-
genic cancer cells based on the expression of cell sur-
face markers. A small subpopulation of cells character-
ized by a CD44high/CD24low phenotype was capable of
generating tumors in a xenograft model more effectively
than a CD44low/CD24high subpopulation of cells. Strik-
ingly, EMT activation in immortalized human mammary
epithelial cells by either TGF-1 exposure or overexpres-
sion of the EMT-inducing transcription factors Snail or
Twist induces cells to adopt a CD44high/CD24low stem
cell–like profile. In addition, this population of CD44high/
CD24low cells showed mesenchymal traits and stem cell
properties, such as enhanced mammosphere-forming
ability and differentiation into cells expressing lineage-
specific markers of myoepithelial or luminal epithelial
cells.93
These seminal experiments suggest that EMT is suffi-
cient to stimulate a subpopulation of cells to acquire stem
cell–like properties. Cripto-1 is an inducer of EMT during
embryogenesis, and recent reports94 have shown that
Cripto-1 is enriched in a subpopulation of cancer cells
with stem-like characteristics, suggesting a link between
CSCs and EMT in these cells. For instance, two distinct
subpopulations of cells expressing high and low levels of
Cripto-1 have been identified in human EC cells.94 These
EC cell subpopulations, expressing different levels of
Cripto-1 on the cell surface, were isolated by fluores-
cence-activated cell sorter analysis and demonstrated
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cell subpopulation expressing high levels of Cripto-1
formed tumor spheres in serum-free suspension cultures
with a higher efficiency than the low Cripto-1–expressing
EC cell fraction. In addition, both fractions of EC cells
were injected s.c. into nude mice, and the Cripto-1 high
EC cell expression fraction produced larger tumors and
appeared with a shorter tumor latency period compared
with tumors derived from the low Cripto-1–expressing EC
cells. Finally, in the high Cripto-1–expressing EC sub-
population of cells, Cripto-1 expression was positively
regulated by ES pluripotential stem cell transcription fac-
tors Nanog and Oct-4 and by an Smad2/3-dependent
signaling pathway involving Activin, Nodal, GDF1, or
GDF3.94
Similarly, activation of the Nodal/Cripto-1 signaling
pathway has regulated self-renewal and in vivo tumorige-
nicity of pancreatic CSCs.95 Inhibition of Nodal/Activin/
Cripto-1 signaling through either pharmacological inhibi-
tion or short hairpin RNA technology reversed the
chemoresistance of orthotopically engrafted pancreatic
CSCs to gemcitabine,95 providing a novel therapeutic
approach to target pancreatic CSCs. In addition, Cripto-1
has been identified in a small subpopulation of stem-like
cells in hormone-responsive and nonresponsive prostate
tumor cells, and in human melanomas.5 Finally, in the
bone marrow hematopoietic niche, Cripto-1 expression in
the stroma was essential in regulating the lineage spec-
ification of a CD34/GRP78 myeloid progenitor population
under hypoxic conditions.96 This finding might be signif-
icant, because hypoxia can directly enhance Cripto-1
expression through the binding of hypoxia-inducible fac-
tor-1 to hypoxia-responsive elements within the Cripto-1
promoter region (Figure 2 and Table 1).37
A recent report97 highlights the signaling pathways
that induce and maintain an EMT program in mammary
epithelial cells. The authors analyzed the proteins se-
creted into the culture medium of immortalized human
mammary epithelial cells that either display a CD44high/
CD24low cell surface marker profile or were overexpress-
ing the transcription factor Twist using an antibody array.
Interestingly, Cripto-1, together with other TGF- family
members, Wnt signaling molecules, and proangiogenic
factors, was among the secreted proteins that were de-
tected in mammary epithelial cells undergoing EMT, sug-
gesting the activation of autocrine signaling loops during
EMT. Therefore, TGF- signaling, in collaboration with
canonical and noncanonical Wnt signaling pathways,
can establish cooperating autocrine and paracrine sig-
naling loops that can induce EMT in mammary epithelial
cells. However, in the normal mammary gland, these
secreted growth factors fail to induce EMT because of the
concomitant secretion of TGF-/Nodal and Wnt signaling
pathway inhibitors, such as Lefty, Cerberus, dickkopf1,
secreted frizzled-related proteins, and BMPs.
Conclusions
This review has highlighted the importance of Cripto-1
in regulating cell plasticity and EMT during embryo-genesis, mammary gland development, and cancer.
Targeting molecular signals that lead to both the EMT
switch in tumor cells and the emergence of dedifferen-
tiated cancer cells with stem-like properties is a prom-
ising therapeutic strategy. Several studies have shown
that pharmacological agents that target Cripto-1 in
cancer have therapeutic value.98 Therefore, therapeu-
tic strategies inhibiting the induction of EMT may re-
duce the formation of cancer stem-like cells and im-
prove clinical outcome.
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